{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T03:45:32Z","timestamp":1787975132730,"version":"build-2784847793"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lungcancerjournal.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1016\/j.lungcan.2021.08.014","type":"journal-article","created":{"date-parts":[[2021,8,31]],"date-time":"2021-08-31T11:53:25Z","timestamp":1630410805000},"page":"9-17","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":31,"special_numbering":"C","title":["ALK inhibitor-induced bradycardia: A systematic-review and meta-analysis"],"prefix":"10.1016","volume":"161","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8420-7628","authenticated-orcid":false,"given":"Filipe","family":"Cirne","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shijie","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8166-5885","authenticated-orcid":false,"given":"Coralea","family":"Kappel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8322-7184","authenticated-orcid":false,"given":"Adam","family":"El-Kadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carly C.","family":"Barron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1590-2130","authenticated-orcid":false,"given":"Peter M.","family":"Ellis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8456-5823","authenticated-orcid":false,"given":"Stephanie","family":"Sanger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1968-169X","authenticated-orcid":false,"given":"Darryl P.","family":"Leong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.lungcan.2021.08.014_b0005","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.lungcan.2020.04.011","article-title":"Efficacy and safety of ALK inhibitors in ALK-rearranged non-small cell lung cancer: A systematic review and meta-analysis","volume":"144","author":"Breadner","year":"2020","journal-title":"Lung Cancer."},{"issue":"2","key":"10.1016\/j.lungcan.2021.08.014_b0010","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.cllc.2011.08.005","article-title":"Efficacy of EGFR tyrosine kinase inhibitors in patients with EGFR-mutated nonsmall-cell lung cancer: A meta-analysis of 13 randomized trials","volume":"13","author":"Petrelli","year":"2012","journal-title":"Clinical Lung Cancer."},{"issue":"2","key":"10.1016\/j.lungcan.2021.08.014_b0015","doi-asserted-by":"crossref","first-page":"e0229179","DOI":"10.1371\/journal.pone.0229179","article-title":"ALK inhibitors for non-small cell lung cancer: A systematic review and network meta-analysis","volume":"15","author":"Elliott","year":"2020","journal-title":"PLoS ONE"},{"issue":"23","key":"10.1016\/j.lungcan.2021.08.014_b0020","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1056\/NEJMoa1408440","article-title":"First-Line Crizotinib versus Chemotherapy in ALK -Positive Lung Cancer","volume":"371","author":"Solomon","year":"2014","journal-title":"New Engl. J. Med."},{"issue":"1","key":"10.1016\/j.lungcan.2021.08.014_b0025","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1177\/1758834015617355","article-title":"ALK inhibitors in non-small cell lung cancer: The latest evidence and developments","volume":"8","author":"Sullivan","year":"2016","journal-title":"Therapeut. Adv. Med. Oncol."},{"issue":"12","key":"10.1016\/j.lungcan.2021.08.014_b0030","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1097\/JTO.0b013e3182307e06","article-title":"Asymptomatic profound sinus bradycardia (heart rate \u226445) in non-small cell lung cancer patients treated with crizotinib","volume":"6","author":"Ou","year":"2011","journal-title":"J. Thorac. Oncol."},{"issue":"4","key":"10.1016\/j.lungcan.2021.08.014_b0035","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1002\/cam4.622","article-title":"Factors associated with sinus bradycardia during crizotinib treatment: A retrospective analysis of two large-scale multinational trials (PROFILE 1005 and 1007)","volume":"5","author":"Ou","year":"2016","journal-title":"Cancer Medicine."},{"issue":"3","key":"10.1016\/j.lungcan.2021.08.014_b0040","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1007\/s00280-017-3253-5","article-title":"Effect of alectinib on cardiac electrophysiology: Results from intensive electrocardiogram monitoring from the pivotal phase II NP28761 and NP28673 studies","volume":"79","author":"Morcos","year":"2017","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"7","key":"10.1016\/j.lungcan.2021.08.014_b0045","doi-asserted-by":"crossref","first-page":"467","DOI":"10.7326\/M18-0850","article-title":"PRISMA extension for scoping reviews (PRISMA-ScR): Checklist and explanation","volume":"169","author":"Tricco","year":"2018","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.lungcan.2021.08.014_b0050","unstructured":"NCT01822496, Erlotinib Hydrochloride or Crizotinib and Chemoradiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer, Https:\/\/Clinicaltrials.Gov\/Show\/Nct01822496. (2013)."},{"issue":"10072","key":"10.1016\/j.lungcan.2021.08.014_b0055","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/S0140-6736(17)30123-X","article-title":"First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study","volume":"389","author":"Soria","year":"2017","journal-title":"The Lancet."},{"issue":"25","key":"10.1016\/j.lungcan.2021.08.014_b0060","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1056\/NEJMoa1214886","article-title":"Crizotinib versus Chemotherapy in Advanced ALK -Positive Lung Cancer","volume":"368","author":"Shaw","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lungcan.2021.08.014_b0065","doi-asserted-by":"crossref","unstructured":"Y.L. Wu, S. Lu, Y. Lu, J. Zhou, Y. kai Shi, V. Sriuranpong, J.C.M. Ho, C.K. Ong, C.M. Tsai, C.H. Chung, K.D. Wilner, Y. Tang, E.T. Masters, P. Selaru, T.S. Mok, Results of PROFILE 1029, a Phase III Comparison of First-Line Crizotinib versus Chemotherapy in East Asian Patients with ALK-Positive Advanced Non\u2013Small Cell Lung Cancer, J. Thorac. Oncol. 13 (2018) 1539\u20131548. https:\/\/doi.org\/10.1016\/j.jtho.2018.06.012.","DOI":"10.1016\/j.jtho.2018.06.012"},{"issue":"10089","key":"10.1016\/j.lungcan.2021.08.014_b0070","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(17)30565-2","article-title":"Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial","volume":"390","author":"Hida","year":"2017","journal-title":"The Lancet."},{"issue":"9","key":"10.1016\/j.lungcan.2021.08.014_b0075","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1056\/NEJMoa1704795","article-title":"Alectinib versus Crizotinib in Untreated ALK -Positive Non\u2013Small-Cell Lung Cancer","volume":"377","author":"Peters","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lungcan.2021.08.014_b0080","doi-asserted-by":"crossref","unstructured":"D.R. Camidge, H.R. Kim, M.J. Ahn, J.C.H. Yang, J.Y. Han, M.J. Hochmair, K.H. Lee, A. Delmonte, M.R. Garc\u00eda Campelo, D.W. Kim, F. Griesinger, E. Felip, R. Califano, A. Spira, S.N. Gettinger, M. Tiseo, H.M. Lin, N. Gupta, M.J. Hanley, Q. Ni, P. Zhang, S. Popat, Brigatinib Versus Crizotinib in Advanced ALK Inhibitor\u2013Naive ALK-Positive Non\u2013Small Cell Lung Cancer: Second Interim Analysis of the Phase III ALTA-1L Trial, J. Clin. Oncol.. 38 (2020) 3592\u20133603. https:\/\/doi.org\/10.1200\/JCO.20.00505.","DOI":"10.1200\/JCO.20.00505"},{"issue":"5","key":"10.1016\/j.lungcan.2021.08.014_b0085","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/S2213-2600(19)30053-0","article-title":"Alectinib versus crizotinib in untreated Asian patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer (ALESIA): a randomised phase 3 study","volume":"7","author":"Zhou","year":"2019","journal-title":"Lancet Respirat. Med."},{"issue":"21","key":"10.1016\/j.lungcan.2021.08.014_b0090","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1056\/NEJMoa2027187","article-title":"First-Line Lorlatinib or Crizotinib in Advanced ALK -Positive Lung Cancer","volume":"383","author":"Shaw","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.lungcan.2021.08.014_b0095","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1093\/annonc\/mdy121","article-title":"Alectinib versus chemotherapy in crizotinibpretreated anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer: Results from the phase III ALUR study","volume":"29","author":"Novello","year":"2018","journal-title":"Ann. Oncol."},{"issue":"7","key":"10.1016\/j.lungcan.2021.08.014_b0100","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1016\/S1470-2045(17)30339-X","article-title":"Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial","volume":"18","author":"Shaw","year":"2017","journal-title":"Lancet Oncol."},{"issue":"1","key":"10.1016\/j.lungcan.2021.08.014_b0105","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1136\/ebmed-2017-110882","article-title":"Catalogue of bias: allocation bias","volume":"23","author":"Nunan","year":"2018","journal-title":"BMJ Evid.-Based Med."},{"key":"10.1016\/j.lungcan.2021.08.014_b0110","unstructured":"C.O. of the. U.S., Food and Drug Administration. FDA., (2021). https:\/\/www.fda.gov\/home (accessed April 26, 2021)."},{"key":"10.1016\/j.lungcan.2021.08.014_b0115","first-page":"1","article-title":"Crizotinib inhibits hyperpolarization-activated cyclic nucleotide-gated channel 4 activity","volume":"3","author":"Zhang","year":"2017","journal-title":"Cardio-Oncol."},{"issue":"21","key":"10.1016\/j.lungcan.2021.08.014_b0120","doi-asserted-by":"crossref","first-page":"5302","DOI":"10.1002\/cncr.27450","article-title":"Rapid-onset hypogonadism secondary to crizotinib use in men with metastatic nonsmall cell lung cancer","volume":"118","author":"Weickhardt","year":"2012","journal-title":"Cancer"},{"issue":"11","key":"10.1016\/j.lungcan.2021.08.014_b0125","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1002\/cncr.28040","article-title":"Heart rate decrease during crizotinib treatment and potential correlation to clinical response","volume":"119","author":"Ou","year":"2013","journal-title":"Cancer"},{"issue":"1106","key":"10.1016\/j.lungcan.2021.08.014_b0130","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1136\/postgradmedj-2017-135213","article-title":"Severe bradycardia associated with crizotinib","volume":"93","author":"Kwan Lung","year":"2017","journal-title":"Postgrad. Med. J."},{"issue":"7","key":"10.1016\/j.lungcan.2021.08.014_b0135","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1586\/14737140.2015.1045493","article-title":"When crizotinib-induced bradycardia becomes symptomatic: Role of concomitant drugs","volume":"15","author":"Gallucci","year":"2015","journal-title":"Expert Rev. Anticancer Ther."}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500221005158?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500221005158?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T12:50:42Z","timestamp":1759236642000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500221005158"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11]]},"references-count":27,"alternative-id":["S0169500221005158"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2021.08.014","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2021,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"ALK inhibitor-induced bradycardia: A systematic-review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2021.08.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}